Hepatitis B Vaccination Guidelines

Introduction to Hepatitis B Vaccination

The Centers for Disease Control and Prevention (CDC) recommends that individuals who receive 3 doses of the Hepatitis B virus (HBV) vaccine will have positive Hepatitis B surface antibody (HBsAb/anti-HBs) in their serum, indicating immunity, with the vaccine containing purified hepatitis B surface antigen (HBsAg) that stimulates the immune system to produce antibodies against this antigen (anti-HBs), providing protection against HBV infection 1

A protective anti-HBs level (≥10 mIU/mL) indicates successful immunization, with HBsAg, HBeAg, and HBcAb/anti-HBc typically negative in vaccinated individuals, as recommended by the CDC 1, 2
The presence of HBsAg, HBeAg, and HBcAb/anti-HBc can indicate natural HBV infection, while vaccination only produces anti-HBs, as stated by the CDC 1

Postvaccination serologic testing is recommended 1-2 months after the final dose for certain groups, such as healthcare personnel and immunocompromised individuals, to assess immune response, with testing for anti-HBs performed 1-2 months after the final vaccine dose, as recommended by the CDC 1, 2

Anti-HBs levels may decline over time after vaccination, but immunologic memory typically persists and provides ongoing protection, with the CDC recommending administering one additional dose of hepatitis B vaccine followed by anti-HBs testing 1-2 months later for individuals who test negative for hepatitis B surface antibody (anti-HBs <10 mIU/mL) after completing the standard 3-dose hepatitis B vaccine series 1
For non-responders, the initial approach is to administer a single dose of hepatitis B vaccine immediately, and then test for anti-HBs 1-2 months after this additional dose, with several factors associated with diminished immune response to hepatitis B vaccination, including age >40 years, smoking, obesity, genetic factors, and immune suppression 1, 2, 3
If anti-HBs ≥10 mIU/mL after the additional dose, the person is considered protected and needs no further vaccination; however, if anti-HBs remains <10 mIU/mL, proceeding to complete a second series is recommended, with the CDC and ACIP advising against more than two complete vaccine series in non-responders 1, 2
Non-responders should be informed that they remain susceptible to HBV infection, advised about precautions to prevent HBV infection, and emphasized the need for hepatitis B immune globulin (HBIG) prophylaxis after any known or likely exposure to HBsAg-positive blood, as per CDC guidelines 1, 2

If exposed to HBsAg-positive source or high-risk source, administer two doses of HBIG, one month apart, with immediate administration (preferably within 24 hours) recommended for occupational exposure to HBV if the source is HBsAg-positive, and revaccination or two doses of HBIG, one month apart, for those who failed one or two complete series, respectively 2, 4
If the source is HBsAg-negative, no treatment is needed, but if the source status is unknown, treat as if the source were HBsAg-positive if it is a high-risk source, otherwise test the exposed person for anti-HBs 2, 4